Moderna stock is trading -34.97% below its average target price of $145.2 after dropping -20.8% during today's afternoon session. Analysts are giving the Large-Cap Biotechnology company an average rating of hold and target prices ranging from $62.0 to $310.0 per share.
The stock has an average amount of shares sold short at 7.8%, and a short ratio of 6.13. The company's insiders own 9.55% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 72.8% of Moderna's shares being owned by this investor type.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Baillie Gifford and Company | 11% | 43,449,041 | $4,102,458,371 |
| 2024-03-31 | Vanguard Group Inc | 10% | 39,036,872 | $3,685,861,382 |
| 2024-03-31 | Blackrock Inc. | 7% | 25,395,878 | $2,397,878,754 |
| 2024-03-31 | State Street Corporation | 4% | 14,452,035 | $1,364,561,118 |
| 2024-03-31 | FMR, LLC | 4% | 13,599,837 | $1,284,096,584 |
| 2024-03-31 | Flagship Pioneering Inc. | 3% | 9,666,038 | $912,667,290 |
| 2024-03-31 | Theleme Partners LLP | 2% | 7,321,797 | $691,324,059 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 6,750,479 | $637,380,214 |
| 2024-03-31 | Wellington Management Group, LLP | 1% | 5,604,703 | $529,196,046 |
| 2024-03-31 | Morgan Stanley | 1% | 5,493,965 | $518,740,165 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Moderna.
